Table 1 |
||||
|
Peptides used in this study. |
||||
|
Peptide |
Amino Acid Position |
Sequence |
MW |
Maximum Solubility (μM)* |
|
|
||||
|
Pcr-400 |
gp21 400–429 |
CCFLNITNSHVSILQERPPLENRVLTGWGL |
3,411 |
> 90.00 |
|
Pcr-400 L/A |
gp21 400–429 |
---A---------A-----A----A----A |
3,200 |
45.00 |
|
PBLV-391 |
gp30 391–419 |
CCFLRIQNDSIIRLGDLQPLSQRVSTDWQ |
3,447 |
> 90.00 |
|
PBLV-ΔN |
gp30 400–419 |
S------------------- |
2,312 |
> 90.00 |
|
PBLV-ΔC |
gp30 391–410 |
-------------------L |
2,317 |
> 90.00 |
|
PBLV-L/A |
gp30 391–419 |
---A---------A--A--A--------- |
3,236 |
45.00 |
|
PBLV-L404/410A |
gp30 391–419 |
-------------A-----A--------- |
3,321 |
> 90.00 |
|
PBLV-ΔCCF |
gp30 394–419 |
L------------------------- |
3,052 |
11.25 |
|
PBLV-R403A |
gp30 391–419 |
------------A---------------- |
3,321 |
22.50 |
|
C34 |
gp41 627–661 |
GWMEWDREINNYTSLLIHSLIEESQNQQEKNEQELL |
4,418 |
> 90.00 |
|
|
||||
|
* Maximum solubility in aqueous solution determined by laser nephelometry. |
||||
|
Lamb et al. Retrovirology 2008 5:70 doi:10.1186/1742-4690-5-70 |
||||
